(1S,2S)-(+)-trans-2-ethylcyclopentanol | 83708-72-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1S,2S)-(+)-trans-2-ethylcyclopentanol
• 英文别名: (1S,2S)-2-ethylcyclopentan-1-ol
• CAS: 83708-72-9
• 化学式: C₇H₁₄O
• 分子量: 114.188
• InChiKey: MNTAIMBGDYAZCM-BQBZGAKWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-乙基-1-环戊烯 在 甲醇 、 sodium hydroxide 、 双氧水 、 (-)-Monoisopinocampheylborane 作用下， 生成 (1S,2S)-(+)-trans-2-ethylcyclopentanol 、 trans-2-Aethyl-cyclopentanol
  参考文献：
  名称：

  Hydroboration. 62. Monoisopinocampheylborane; an excellent chiral hydroborating agent for trans-disubstituted and trisubstituted alkenes. Evidence for a strong steric dependence in such asymmetric hydroborations

  摘要：

  DOI：

  10.1021/jo00147a006

文献信息

• FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF
  申请人：Tabomedex Biosciences, LLC

  公开号：US20170190713A1

  公开（公告）日：2017-07-06

  Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

  本文提供了作为MK2抑制剂有用的替代融合四环化合物。本发明还提供了所述化合物的药物组合物。本发明还提供了替代融合四环化合物的医药用途。
• ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20160229813A1

  公开（公告）日：2016-08-11

  The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的苯并喹唑啉酮化合物，它们是M1受体正变构调节剂，可用于治疗与M1受体有关的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包括这些化合物的制药组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物的用途。
• SALT AND POLYMORPHIC FORMS OF (3R,4S)-L-((4-AMINO-5H-PYRROLO[3,2,-D]PYRIMIDIN-7-YL)METHYL)-4(METHYLTHIOMETHYL)PYRODIN-3-OL(MTDIA)
  申请人：Victoria Link Limited

  公开号：US20150274741A1

  公开（公告）日：2015-10-01

  The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5′-methylthioadenosine phosphorylase (MTAP).

  本发明涉及（3R，4S）-1-（（4-氨基-5H-吡咯并[3,2-d]嘧啶-7-基）甲基）-4-（甲硫甲基）吡咯烷-3-醇的盐形式，以及盐的多形式。本发明还涉及制备盐形式的过程，并且涉及在治疗希望抑制5'-甲基硫腺苷磷酸化酶（MTAP）的疾病和疾病中使用盐形式。
• [EN] 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS<br/>[FR] COMPOSÉS 2,8-DIAZASPIRO[4.5]DÉCANES
  申请人：GENENTECH INC

  公开号：WO2022253341A1

  公开（公告）日：2022-12-08

  Disclosed are 2, 8-diazaspiro [4.5] decane compounds, including (pyrido [3, 4-d] pyrimidin-4-yl) -2, 8-diazaspiro [4.5] decane compounds, (2, 6-naphthyridin-1-yl) -2, 8-diazaspiro [4.5] decane compounds, and (1, 7-naphthyridin-4-yl) -2, 8-diazaspiro [4.5] decane compounds, that are inhibitors of LATS1/2, compositions containing these compounds, and methods for inhibiting LATS1/2 activity.

  本发明涉及2,8-二氮杂螺[4.5]癸烷化合物，包括(吡啶并[3,4-d]嘧啶-4-基)-2,8-二氮杂螺[4.5]癸烷化合物，(2,6-萘啶基)-2,8-二氮杂螺[4.5]癸烷化合物，以及(1,7-萘啶基-4-基)-2,8-二氮杂螺[4.5]癸烷化合物，它们是LATS1/2的抑制剂，以及含有这些化合物的组合物和抑制LATS1/2活性的方法。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3643718A1

  公开（公告）日：2020-04-29

  The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

  本发明旨在提供一种可用于预防或治疗便秘等疾病的化合物。本发明提供了由下式（I）代表的化合物： 其中各符号如说明书所述，或其盐。